The Health Outcomes Observatory (H2O) project kicks off with the aim of giving patients in Europe a more influential voice. Not only in medical decisions that affect them, but also in how healthcare systems can provide the best and most efficient care for all patients in the future. Read this press release and learn why 23 world-leading institutions—including university hospitals, patient groups, and pharma industry—are joining together to design the health data infrastructure of the future with the support of the Innovative Medicines Initiative (IMI).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/